Is there a benefit for CYP2C19 genotype-guided antiplatelet treatment in elderly acute coronary syndrome patients?

References

• 1. Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur. J. Cardiothorac. Surg. 53(1), 34–78 (2017).
  Google Scholar
• 2. Collet J-P, Thiele H, Barbato E et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 42(14), 1289–1367 (2020).
  Google Scholar
• 3. Wiviott SD, Braunwald E, McCabe CH et al. TRITON-TIMI 38: prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–15 (2007).
  Medline CASGoogle Scholar
• 4. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–57 (2009).
  Medline CASGoogle Scholar
• 5. Yeh RW, Secemsky EA, Kereiakes DJ et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention original investigation. JAMA 315(16), 1735–1749 (2016).
  Medline CASGoogle Scholar
• 6. Saar A, Marandi T, Ainla T, Fischer K, Blöndal M, Eha J. The risk-treatment paradox in non-ST-elevation myocardial infarction patients according to their estimated GRACE risk. Int. J. Cardiol. 272, 26–32(2018).
  MedlineGoogle Scholar
• 7. Gimbel ME, Tavenier AH, Bor W et al. Ticagrelor versus clopidogrel in older patients with NSTE-ACS using oral anticoagulation: asub-analysis of the POPular age trial. J. Clin. Med. 9(10), 3249 (2020).
  CASGoogle Scholar
• 8. Cayla G, Cuisset T, Silvain J et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 388(10055), 2015–2022 (2016).
  Medline CASGoogle Scholar
• 9. Sibbing D, Gross L, Trenk D et al. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. European Heart Journal 39(29),), 2749–2758 (2019).
  Google Scholar
• 10. Claassens DMF, Vos GJA, Bergmeijer TO et al. A genotype-guided strategy for oral P2Y 12 inhibitors in primary PCI. N. Engl. J. Med. 381(17), 1621–1631 (2019).
  Medline CASGoogle Scholar
• 11. Claassens DMF, Gimbel ME, Bergmeijer TO et al. Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: a pre-specified sub analysis from the POPular Genetics and POPular age trials CYP2C19 alleles in elderly patients. Int. J. Cardiol. 334, 10–17 (2021).
  MedlineGoogle Scholar
• 12. Husted S, James S, Becker RC et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: asubstudy from the prospective randomized PLATelet inhibition and patient outcomes (PLATO) trial. Circ. Cardiovasc. Qual. Outcomes 5(5), 680–688 (2012).
  MedlineGoogle Scholar
• 13. Schmucker J, Fach A, Mata Marin LA et al. Efficacy and safety of ticagrelor in comparison to clopidogrel in elderly patients with ST-segment-elevation myocardial infarctions. J. Am. Heart Assoc. 8(18), e012530 (2019)
  MedlineGoogle Scholar
• 14. Szummer K, Montez-Rath ME, Alfredsson J et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART registry. Circulation 142(18), 1700–8 (2020).
  Medline CASGoogle Scholar
• 15. Pereira NL, Rihal C, Lennon R et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: ameta-analysis. JACC Cardiovasc. Interv. 14(7), 739–750 (2021).
  MedlineGoogle Scholar
• 16. Angiolillo DJ, Capodanno D, Danchin N et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovasc. Interv. 13(5), 606–617 (2020).
  MedlineGoogle Scholar